

TABLE OF CONTENTS

CHAPTER 1

Introduction

CHAPTER 2

State Common Law Claims Based Upon Informational Defects

§ 2.01	Introduction	2.01-2
§ 2.02	The Duty to Warn and Unavoidably Unsafe Product Doctrine	2.02-1
[1]	Unavoidably Unsafe Products and Design Defects	2.02-15
[2]	Prescription Medical Devices and Biologics as Unavoidably Unsafe Products	2.02-16
[3]	Case-by-Case Versus Categorical Application of the Unavoidably Unsafe Product Doctrine	2.02-26
§ 2.03	The Learned Intermediary Rule	2.03-1
[1]	The Learned Intermediary Rule as the Distinctive Attribute of Litigation Involving Prescription Medical Products	2.03-3
[2]	Who Is the Learned Intermediary?	2.03-69
[3]	Exceptions to the Learned Intermediary Rule	2.03-79
[a]	Over-the-Counter Drugs	2.03-79
[b]	Mass Immunization Exception	2.03-81
[c]	FDA-Mandated Patient Warning Exception	2.03-85
[d]	Personal Choice Product Exception	2.03-88
[e]	Direct-to-Consumer Marketing Exception	2.03-92

	[f] FDA Recall Exception	2.03-96
	[g] Financial and Other Prescriber Incentives Exception	2.03-97
	[h] Miscellaneous Unrecognized Exceptions	2.03-100
§ 2.04	Adequacy of Warnings	2.04-1
	[1] Pleading Requirements for Warnings Adequacy	2.04-1
	[2] Criteria for an Adequate Warning	2.04-5
	[3] Establishing the Adequacy of a Warning as a Matter of Law	2.04-72
§ 2.05	Establishing Causation in a Warning Case	2.05-1
	[1] Pleading Requirements for Warning Causation	2.05-1
	[2] When an Inadequate Warning Is Non-Causal	2.05-4
	[3] Issues of Fact Concerning Warning Causation	2.05-62
	[4] The Presumption That an Inadequate Warning Is Causal	2.05-79
	[5] Other Causation Issues in Warning Cases	2.05-97
	[6] Miscellaneous Causation Issues in Warning Claims	2.05-115
§ 2.06	Overpromotion and Negligent Marketing Claims	2.06-1
§ 2.07	Implied Warranty Claims	2.07-1
§ 2.08	Express Warranty Claims	2.08-1
§ 2.09	Illegal Promotion and Marketing Claims	2.09-1
§ 2.10	Duty to Warn Claims Involving Direct Patient Warnings	2.10-1
§ 2.11	Warning Claims Brought by Prescribing Physicians or Hospitals	2.11-1
§ 2.12	Public Policy Considerations Underlying the Unavoidable Unsafe Product Doctrine and the Learned Intermediary Rule	2.12-1
§ 2.13	Fraud/Intentional Misrepresentation	2.13-1
§ 2.14	Negligent Misrepresentation	2.14-1
§ 2.15	State Consumer Protection Acts	2.15-1
§ 2.16	Federal RICO Claims	2.16-1

CHAPTER 3

**State Common Law Claims Based Upon
Non-Informational Defects**

§ 3.01	Introduction—Design Defect Claims	3.01-2
§ 3.02	Claims Sounding In Strict Liability	3.02-1
	[1] Strict Liability—Pleading and Merger of Other Causes of Action	3.02-3
	[2] Elements of Strict Liability Claims Brought Under <i>The Restatement</i> (<i>Second</i>) of <i>Torts</i> § 402A	3.02-12
	[3] Requirement of an Unreasonably Dangerous Product	3.02-17
	[a] Consumer Expectations Test	3.02-21
	[b] Risk-Utility Test	3.02-28
	[c] Hybridization of Consumer Expectations and Risk-Utility Tests	3.02-41
	[d] The Role of the Feasible Safer Alternative Design	3.02-45
	[e] Injury Alone Is Not Sufficient to Establish an Unreasonably Dangerous Product	3.02-70
	[4] The Unavoidably Unsafe Product Doctrine	3.02-76
	[a] Relationship of the Unavoidably Unsafe Product Doctrine to Design Defect Claims	3.02-76
	[b] Role of the Risk-Utility Test Under the Unavoidably Unsafe Product Doctrine	3.02-91
	[c] Role of Feasible Safer Alternative Design Under the Unavoidably Unsafe Product Doctrine	3.02-94
	[5] Requirements of Injury and Proximate Cause	3.02-97
§ 3.03	Design Defect Claims Under the <i>Restatement</i> (<i>Third</i>) of <i>Torts: Products Liability</i>	3.03-1
§ 3.04	Design Defect Claims Sounding in Negligence	3.04-1
§ 3.05	Manufacturing Defects	3.05-1
	[1] Introduction	3.05-1
	[2] The <i>Restatement</i> Formulation of Manufacturing Defect	3.05-15
	[3] Plaintiff’s Prima Facie Manufacturing Defect Case	3.05-18

	[4] Rebutting Plaintiff's <i>Prima Facie</i> Case of Manufacturing Defect	3.05-28
§ 3.06	Medical Monitoring	3.06-1
§ 3.07	Independent Duty to Test	3.07-1
§ 3.08	Market Share Liability	3.08-1
§ 3.09	Cognizable Injury	3.09-1
§ 3.10	Miscellaneous Claims	3.10-1
	[1] Duty to Recall	3.10-1
	[2] Restitution/Unjust Enrichment	3.10-6
	[3] Lanham Act	3.10-18
	[4] Redhibition	3.10-18
	[5] Failure to Train	3.10-21
	[6] Intentional/Negligent Infliction of Emotional Distress	3.10-23
	[7] Miscellaneous Federal Claims	3.10-28
	[8] Miscellaneous State Law Claims	3.10-32

CHAPTER 4

The Federal Framework

§ 4.01	What Litigators Need to Know About the FDA	4.01-2
	[1] Introduction	4.01-2
	[2] FDA Approval Processes for Prescription Medical Products	4.01-3
	[a] Prescription Drugs	4.01-9
	[b] Medical Devices	4.01-24
	[c] Generic Drugs	4.01-35
	[d] Biologics	4.01-37
	[e] Biosimilars	4.01-37
	[f] Combination Products	4.01-39
	[3] Post-Approval FDA Regulation	4.01-40
	[4] Off-Label Use	4.01-54
§ 4.02	The Food, Drug and Cosmetic Act as a Source of Substantive Tort Law	4.02-1
	[1] No Private Food, Drug and Cosmetic Act Right of Action	4.02-1
	[2] Negligence <i>Per Se</i> and Related Doctrines	4.02-12
	[a] General Negligence <i>Per Se</i> Principles Applicable to Prescription Medical Product Liability Litigation	4.02-12
	[b] The Viability of Negligence <i>Per Se</i> Claims Based Upon Allegations of FDCA Violations	4.02-26

	[i] Arguments in Favor of Allowing FDCA-Based Negligence <i>Per Se</i>	4.02-27
	[ii] Arguments in Favor of Rejecting FDCA-Based Negligence <i>Per Se</i>	4.02-33
[3]	Defenses to FDCA-Based Negligence <i>Per Se</i> Claims	4.02-50
	[a] Defense on the Merits/No Violation	4.02-50
	[b] Non-Statutory Violations.	4.02-54
	[c] Imposition of Novel Duties.	4.02-59
	[d] Allegations Concerning the FDA Approval Process.	4.02-68
	[e] Violations of Vague or Generic Enactments.	4.02-72
	[f] Causation Issues in FDCA-Based Negligence <i>Per Se</i>	4.02-79
§ 4.03	Impact of Medicare Secondary Payer Legislation	4.03-1

CHAPTER 5

**Federal Preemption as a Defense to Drug and
Medical Device Litigation**

§ 5.01	Express Preemption.	5.01-4
	[1] General Considerations Concerning Express Preemption	5.01-4
	[2] Application of Express Preemption to Common Law Tort Claims	5.01-9
	[3] Express Preemption and Medical Devices.	5.01-11
	[a] Express Preemption and Substantially Equivalent Devices: <i>Lohr</i> and its Progeny	5.01-12
	[b] Express Preemption and Premarket Approved Devices: <i>Riegel</i> and its Progeny	5.01-19
	[c] Express Preemption Issues Following <i>Riegel</i> and <i>Lohr</i>	5.01-22
	[i] Preemption Issues Involving Multi-Component Device Systems	5.01-37

DRUG AND MEDICAL DEVICE DESKBOOK

	[ii]	Violation, “Identity of Requirements,” or “Parallel” Claims	5.01-40
	[iii]	Effect of Off-Label Use/Promotion on Preemption	5.01-88
	[iv]	Other Claims Not Addressed by the Supreme Court	5.01-98
	[v]	Procedural and Pleading Issues Relating to PMA Medical Device Preemption	5.01-114
	[d]	Express Preemption and Devices on the Market Through Other FDA Procedures	5.01-140
	[i]	Investigational Devices	5.01-140
	[ii]	PMA Supplement Devices	5.01-147
	[iii]	Product Development Protocol and Transitional Devices	5.01-149
	[iv]	Downclassified Devices	5.01-150
	[v]	Reclassified Devices	5.01-150
	[vi]	Combination Devices	5.01-151
	[vii]	Humanitarian Devices	5.01-151
	[e]	Special Cases of Device-Specific Preemption by Regulation	5.01-151
	[i]	Tampon Warnings	5.01-151
	[ii]	Latex Glove Warnings	5.01-154
	[iii]	Contact Lens Care Products	5.01-156
	[iv]	Latex Condoms	5.01-156
	[4]	Express Preemption and Prescription Drugs	5.01-156
	[5]	Express Preemption and Vaccines	5.01-157
	[6]	Express Preemption and Monograph (OTC) Drugs	5.01-162
	[7]	Express Preemption and FDA Decisions Not to Regulate	5.01-174
	[8]	Express Preemption and Informed Consent	5.01-175
	[9]	Express Preemption and the PREP Act	5.04-176
	[10]	Express Preemption and Discovery	5.01-182
§ 5.02		Implied Preemption	5.02-1
	[1]	Field Preemption	5.02-1
	[2]	Conflict Preemption	5.02-3
	[a]	Conflict Preemption by Reason of Impossibility	5.02-3

TABLE OF CONTENTS

xi

	[b] Conflict Preemption by Reason of Obstruction.	5.02-5
[3]	Implied Preemption in Product Liability Litigation	5.02-6
	[a] Effect on Implied Preemption of Express Preemption Clauses	5.02-6
	[b] Effect on Implied Preemption of Express Saving Clauses	5.02-8
[4]	Implied Conflict Preemption in the FDCA Context	5.02-9
	[a] Prescription Drug Labeling and Marketing.	5.02-9
	[i] Background	5.02-9
	[ii] The 2006 FDA Preemption Preamble	5.02-13
	[iii] <i>Wyeth v. Levine</i>	5.02-17
	[iv] <i>Merck Sharp & Dohme Corp. v. Albrecht</i>	5.02-20
	[v] Implied Preemption of Tort Claims Involving Prescription Drugs After <i>Levine</i> and <i>Albrecht</i>	5.02-24
	[vi] Preemption Based on Likely or Actual FDA Rejection of the Relevant Warning.	5.02-34
	[vii] Preemption Based on Unavailability of CBE/FDA Prior Review Requirement.	5.02-55
	[viii] Preemption Based on Interference with the FDCA Regulatory Scheme.	5.02-85
	[b] Generic Drugs	5.02-88
	[c] Paper NDA (§355(b)(2)) Drugs	5.02-117
	[d] Fraud on the FDA	5.02-117
	[e] Private FDCA Enforcement Violation Claims	5.02-142
	[f] Miscellaneous Implied Preemption Situations	5.02-160
	[i] Boxed Warnings	5.02-160
	[ii] Off-label Promotion	5.02-161
	[iii] Failure to Report or to Warn the FDA	5.02-166
	[iv] Monograph (OTC) Drugs	5.02-177
	[v] Other Claims	5.02-178
§ 5.03	Complete Preemption and Federal Question Jurisdiction	5.03-1

CHAPTER 6

Before Litigation Starts: Enhancing Chances for Success

§ 6.01	Introduction	6.01-2
§ 6.02	From the Plaintiff's Perspective	6.02-1
	[1] Factual and Legal Investigation	6.02-1
	[2] The Internet	6.02-2
	[a] Government Web Sites	6.02-2
	[b] Nongovernment Web Sites	6.02-4
§ 6.03	From the Defendant's Perspective	6.03-1
	[1] Prophylactic Planning	6.03-1
	[a] SOPs	6.03-2
	[b] Document Management	6.03-2
	[c] Regulatory and Good Clinical Practice Issues	6.03-4
	[d] Review of Internal and External Documents	6.03-4
	[e] Freedom of Information Act	6.03-5
	[f] Marketing Issues	6.03-5
	[2] Adverse Event Reporting	6.03-7
	[3] Duty to Update Labeling	6.03-10
	[a] Section 10 of the <i>Restatement</i> (<i>Third</i>) of <i>Torts</i>	6.03-12
	[b] Other Causes of Action	6.03-12
	[4] Duty to Warn Regarding Off-Label Use	6.03-13
	[5] Recalls	6.03-14
	[a] Consequences	6.03-15
	[b] Planning for and Executing Recalls	6.03-16
	[6] Clinical Studies	6.03-18
	[a] Clinical Trial Registry	6.03-19
	[b] Integrated Pharmaceutical Networks	6.03-20
	[c] International Clinical Studies	6.03-21
	[d] Remuneration	6.03-21
	[e] Consent	6.03-22
	[f] Termination of Clinical Studies	6.03-25
	[7] "Expanded Access"	6.03-27

CHAPTER 7

Class Actions

§ 7.01	Overview	7.01-3
§ 7.02	Nature of the Certification Determination	7.02-1

TABLE OF CONTENTS

xiii

§ 7.03	Class Actions in Personal Injury Cases	7.03-1
	[1] Tolling of the Statute of Limitations.	7.03-1
	[2] Settlement	7.03-4
§ 7.04	Class Actions for Economic Loss	7.04-1
	[1] Causes of Action	7.04-1
	[2] Grounds for Dismissal of a Claim	7.04-3
	[a] Injury in Fact	7.04-3
	[b] Factual Causation.	7.04-5
	[c] Proximate Causation	7.04-6
§ 7.05	The Elements of a Definable and Ascertainable Class Under Rule 23(a)	7.05-1
	[1] Numerosity	7.05-2
	[2] Commonality.	7.05-4
	[3] Typicality	7.05-5
	[4] Adequacy of Representation	7.05-11
§ 7.06	Criteria for Determining Whether a Mandatory Class Action Can Be Maintained Under Rule 23(b)(1) or Rule 23(b)(2)	7.06-1
	[1] Overview.	7.06-1
	[2] Constitutional Issues.	7.06-2
	[3] Classes Based on Declaratory or Injunctive Relief Under Rule 23(b)(1)(A)	7.06-4
	[4] The “Limited Fund” Class Under Rule 23(b)(1)(B).	7.06-5
	[5] Medical Monitoring Classes Under Rule 23(b)(2)	7.06-9
	[a] Medical Monitoring as Final Injunctive Relief	7.06-10
	[b] Money Damages Cannot Predominate in Rule 23(b)(2) Class.	7.06-13
	[c] The Proposed Class Must Be Cohesive.	7.06-15
§ 7.07	Rule 23(b)(3) and Requirements of Predominance and Superiority	7.07-1
	[1] Predominance	7.07-1
	[a] Problems Inherent in Proposed Nationwide Classes	7.07-1
	[b] Other Individual Issues	7.07-4
	[2] Superiority.	7.07-6
	[3] Manageability	7.07-10
§ 7.08	The Potential for Certification on a Particular Issue.	7.08-1

§ 7.09	Federal Jurisdiction Over Class Actions—The Class Action Fairness Act (CAFA)	7.09-1
	[1] Overview	7.09-1
	[2] Existing Federal Question and Diversity Jurisdiction Unchanged	7.09-1
	[3] Grounds for Diversity Jurisdiction	7.09-3
	[a] \$5 Million Amount in Controversy Requirement	7.09-3
	[b] Minimal Diversity Requirements	7.09-5
	[c] CAFA Applies to Suits with More Than 100 Plaintiffs	7.09-9
	[4] Changes in Rules When Removing Class Actions	7.09-11
	[5] Appellate Review of Remand Orders	7.09-11
§ 7.10	Settlements of Class Actions	7.10-1
	[1] Overview	7.10-1
	[2] Judicial Scrutiny of Class Action Settlements Under CAFA	7.10-1
	[3] Enhanced Judicial Scrutiny of Class Action Settlements Generally	7.10-2
	[4] Required Notice of Class Settlement	7.10-3
§ 7.11	Canadian Pharmaceutical and Medical Device Class Action	7.11-1
	[1] Overview	7.11-1
	[2] Certification Criteria	7.11-2
	[a] “Identifiable Class”	7.11-3
	[b] “Common Issues” Requirement	7.11-4
	[c] “Preferable Procedure”	7.11-4
	[d] Adequate “Representative Plaintiff”	7.11-5
	[3] Settlement Considerations—Opt-In vs. Opt-Out Classes	7.11-6

CHAPTER 8

Non-Manufacturer Defendants in Drug and Medical Device Litigation

§ 8.01	Introduction	8.01-3
§ 8.02	Commercial Distributors	8.02-1
	[1] General Rule of Strict Liability	8.02-1
	[2] <i>Restatement (Third)</i> Position	8.02-8
	[3] Statutory Exceptions to Strict Liability	8.02-9
	[4] Overprescription Theories	8.02-13
	[5] Miscellaneous Intermediate Product Handler	8.02-16

TABLE OF CONTENTS

xv

§ 8.03	Pharmacists	8.03-1
	[1] Majority Rule Rejecting Product Liability Claims Against Pharmacists for Prescribed Drugs	8.03-1
	[2] Minority Rule Allowing Product Liability Claims Against Pharmacists	8.03-20
	[3] Exceptional Circumstances Justifying Imposition of Liability on Pharmacists	8.03-24
	[a] Obvious Inadequacies on Face of Prescription/Failure to Label Properly	8.03-25
	[b] Voluntary Assumption of Duty to Warn	8.03-27
	[c] Specific Knowledge of the Characteristics of a Patient/Customer	8.03-29
	[d] Failure to Warn of Adverse Interaction of Two Prescribed Drugs	8.03-30
	[e] Dispensing Without Valid Prescription	8.03-31
	[f] Failure to Provide FDA-Mandated Materials	8.03-31
	[g] Overprescription Theories	8.03-32
§ 8.04	Bulk and Component Part Sellers	8.04-1
	[1] General Rule	8.04-1
	[2] Federal Law Considerations	8.04-3
	[3] Common Law Considerations	8.04-8
§ 8.05	Hospitals	8.05-1
	[1] Strict Liability	8.05-1
	[a] <i>Restatement</i> Position and the Sale-Service Distinction	8.05-1
	[b] Implied Warranty	8.05-7
	[2] Public Policy Based Rationales for Limiting Hospital Product Liability	8.05-10
	[3] Informed Consent	8.05-13
	[a] No Separate Duty	8.05-13
	[b] Assumption of Duty	8.05-20
	[4] Negligence	8.05-21
	[5] Miscellaneous	8.05-22
§ 8.06	Physicians and Similar Health Care Providers	8.06-1
	[1] Strict Liability/Breach of Implied Warranty	8.06-1
	[2] Informed Consent	8.06-7
	[a] FDA Regulatory Status	8.06-7

	[b] Conflict Of Interest	8.06-9
	[c] Lacking Expert Opinion	8.06-10
§ 8.07	Participants in Clinical Trials	8.07-1
	[1] Monitoring	8.07-1
	[2] Conflicts of Interest	8.07-3
	[3] Product Liability	8.07-4
§ 8.08	Promoters and Co-Promoters	8.08-1
	[1] Wrongful Marketing or Promotion	8.08-1
	[2] First Amendment Defense	8.08-5
	[3] Co-Promoters	8.08-8
	[4] Marketing Consultants	8.08-9
§ 8.09	Original Patent Holders and Inventors	8.09-1
§ 8.10	The Food and Drug Administration and Other Standards-Setting Organizations	8.10-1
§ 8.11	Parents, Subsidiaries and Successors	8.11-1
§ 8.12	Manufacturer Sales Representatives and Other Personnel	8.12-1
§ 8.13	Publishers	8.13-1
§ 8.14	Reprocessors, Repackagers and Relabelers	8.14-1
§ 8.15	Retailers	8.15-1
§ 8.16	Non-profit Patient Assistance Programs	8.16-1

CHAPTER 9

Issues in the Management of the Litigation

§ 9.01	Overview	9.01-3
§ 9.02	Procedural Aggregation	9.02-1
	[1] Initiation of Claims	9.02-1
	[2] Joinder of Plaintiffs	9.02-4
§ 9.03	Collateral Estoppel	9.03-1
§ 9.04	Removal from State Court to Federal Court	9.04-1
	[1] Introduction	9.04-1
	[2] General Principles of Removal	9.04-1
	[3] Removal in Diversity Cases	9.04-3
	[4] Removal in Federal Question Cases	9.04-11
	[5] Federal Officer Removal	9.04-15
§ 9.05	Multidistrict Litigation	9.05-1
	[1] The Commencement of Multidistrict Litigation	9.05-1
	[2] Requirement that Actions to be Transferred Have Common Questions of Fact	9.05-7
	[a] All Actions Before the Panel Must Have One or More Questions of Fact in Common	9.05-7

TABLE OF CONTENTS

xvii

	[b] The Questions of Fact in Common Must Lend Themselves to Resolution Through Centralization	9.05-8
	[c] Commonality Cannot Be Insufficiently Complex	9.05-9
	[d] Transfer Must Be for the Convenience of the Parties and Witnesses	9.05-10
	[e] Transfer Must Promote the Just and Efficient Conduct of Pretrial Proceedings.	9.05-12
[3]	Remand of Actions at Suggestion of Transferee Court.	9.05-14
[4]	Discovery Issues in Multidistrict and Multi-Plaintiff Proceedings	9.05-15
	[a] Introduction—The Beginning of a Multidistrict Litigation	9.05-15
	[b] Discovery of Defendants.	9.05-17
	[i] Document Preservation and Production	9.05-17
	[ii] Other Discovery Issues.	9.05-20
	[c] Discovery of Plaintiffs.	9.05-23
	[d] Case-Specific Expert Discovery Within an MDL.	9.05-29
	[e] Protecting Trade Secrets and Other Confidential Information.	9.05-31
	[i] Drafting a Confidentiality Order	9.05-34
	[ii] Breach of a Confidentiality Order	9.05-41
§ 9.06	Discovery of the FDA	9.06-1
§ 9.07	Relations Between State and Federal Courts.	9.07-1
	[1] Introduction.	9.07-1
	[2] The All Writs Act and the Anti-Injunction Act	9.07-2
	[3] Injunctions in Aid of Jurisdiction	9.07-2
	[4] Injunctions to Protect a Federal Court Judgment	9.07-5

CHAPTER 10

Expert Witnesses

§ 10.01	Introduction	10.01-2
§ 10.02	Types of Experts.	10.02-1

§ 10.03	Discovery and Evaluation of Experts	10.03-1
	[1] Introduction	10.03-1
	[a] Federal Rules Relating to Discovery of Experts	10.03-2
	[b] State Rules Relating to Discovery of Experts	10.03-4
	[c] Discovery of Draft Expert Reports and Counsel's Communications with Experts	10.03-7
	[d] Discovery of Counsel's Communications with the Expert . . .	10.03-10
	[2] Protecting Experts from Unnecessary Disclosure	10.03-12
	[a] Communications between Counsel and Experts	10.03-12
	[b] Communications among Experts	10.03-13
	[c] Withdrawal of the Testifying Expert . .	10.03-13
	[d] Protective Orders	10.03-15
	[3] Expert Witness Evaluation Tools	10.03-16
	[a] Expert Interrogatories	10.03-16
	[b] Expert Depositions and Prior Testimony	10.03-17
	[c] Journals and Publications	10.03-17
	[d] Expert Databases	10.03-17
	[e] Actions by the Office of Research Integrity and the Office for Human Research Protections	10.03-18
	[f] Other Experts	10.03-19
	[g] Documents Produced in the Litigation	10.03-19
	[h] The Industry Client	10.03-19
§ 10.04	Admissibility of Expert Testimony	10.04-1
	[1] Introduction	10.04-1
	[2] <i>Daubert</i> Experience in Drug and Medical Device Litigation	10.04-4
	[a] Expert Opinions Based on Epidemiological Studies and Other Human Studies	10.04-4
	[b] Expert Opinions Based on Case Reports and Adverse Event Reports	10.04-7
	[c] Expert Opinions Based on Animal Studies	10.04-9
	[d] Expert Opinions Based on Similar Drugs	10.04-11

[e] Differential Diagnosis as a Methodology for Proving Causation 10.04-12

[f] Expert Opinions Based on Regulatory Actions 10.04-16

[3] State Law Bases for Admissibility of Expert Testimony 10.04-16

§ 10.05 Challenges to Qualifications 10.05-1

§ 10.06 Expert Testimony on Regulatory Issues 10.06-1

CHAPTER 11

Trial Issues

§ 11.01 Common Evidentiary Issues at Trial 11.01-3

[1] Admissibility of FDA-Related Evidence 11.01-3

[a] Manufacturer-Specific Regulatory History Documents 11.01-3

[b] FDA Reports 11.01-20

[c] FDA Correspondence 11.01-22

[d] Adverse Drug and Medical Device Reports 11.01-24

[e] Evidence of Misstatements to the FDA 11.01-30

[f] Other FDA Evidence 11.01-33

[2] Non-FDA Evidentiary Exclusion Issues 11.01-37

[a] Subsequent Remedial Measures 11.01-37

[b] Similar Incidents 11.01-45

[c] Financial Relationships with Physicians 11.01-52

[d] Notes of Telephone Calls by Sales Representatives 11.01-53

[e] Corporate Motive, State of Mind, and Intent 11.01-53

[f] Warnings, Marketing, and Other Information That Does Not Reach the Prescribing Physician 11.01-62

[g] Foreign Regulatory Proceedings and Decisions 11.01-64

[h] Ghostwriting 11.01-67

[i] Other Evidentiary Issues 11.01-68

[3] FDA Experts 11.01-80

§ 11.02 Bifurcation and Consolidation 11.02-1

[1] Bifurcation 11.02-1

[a] How the Courts View Bifurcation 11.02-1

	[b]	Types of Bifurcation	11.02-3
		[i] General Causation	11.02-3
		[ii] Liability	11.02-4
		[iii] Damages	11.02-5
		[iv] Miscellaneous	11.02-5
	[c]	Arguments for Bifurcation	11.02-5
		[i] Judicial Economy	11.02-5
		[ii] Prejudice	11.02-6
	[d]	Arguments Against Bifurcation	11.02-7
		[i] Sterile Environment	11.02-7
		[ii] Constitutional Limitations	11.02-7
	[e]	Bifurcation of Punitive Damages	11.02-9
	[2]	Consolidation	11.02-12
§ 11.03		Punitive Damages	11.03-1
	[1]	How the States View Punitives	11.03-1
	[2]	Constitutional Standards Governing Punitive Damages After <i>State Farm</i>	11.03-23
	[a]	Reprehensibility	11.03-24
	[b]	The Range of Acceptable Punitive to Compensatory Damages Ratios	11.03-33
	[c]	The “Comparable Civil Penalties” Assessment Is Narrowed	11.03-51
	[d]	Evidentiary Issues After <i>State Farm</i>	11.03-54
		[i] Evidence of Out-of-State Conduct Admissible Only If a “Nexus” to the Harm in the Action Exists	11.03-54
		[ii] Limited Relevance of Evidence of Conduct Injurious to Nonparties	11.03-58
		[iii] Evidence of Dissimilar Conduct Is Barred	11.03-62
		[iv] Net Worth May be Considered, But Cannot Justify an Otherwise Unconstitutional Award	11.03-64
		[v] Expert Testimony on the Amount of Punitive Damages Is Usually Prohibited	11.03-68
	[e]	Conclusion	11.03-69